Duration: Four to six weeks, beginning two to three weeks after fracture (during the transition from soft to hard callus formation)
The medication is FDA-approved for lowering blood sugar levels in patients with type 2 diabetes, reducing the risk of cardiovascular diseases, and promoting weight reduction
Interestingly, the research found a real-world link to symptoms
ACSS2: Acetyl-CoA synthetase 2
Repaglinide stimulates the pancreas to release insulin around meals, while metformin mainly reduces liver glucose production and improves insulin sensitivity
What makes it stand out is that it targets three hormone pathways simultaneously: GLP-1, GIP and glucagon, [which are] involved in hunger, fullness, blood sugar [regulation] and metabolism